Published in Circ Cardiovasc Genet on May 15, 2009
Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study. Circulation (2015) 2.48
Reciprocal transcriptional regulation of metabolic and signaling pathways correlates with disease severity in heart failure. Circ Cardiovasc Genet (2011) 1.68
Electrical remodeling in the failing heart. Curr Opin Cardiol (2010) 1.51
Reverse remodeling in heart failure--mechanisms and therapeutic opportunities. Nat Rev Cardiol (2011) 1.49
Subcellular structures and function of myocytes impaired during heart failure are restored by cardiac resynchronization therapy. Circ Res (2012) 1.44
Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts. Circ Cardiovasc Genet (2009) 1.32
Regulation of pyruvate metabolism and human disease. Cell Mol Life Sci (2013) 1.21
Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart. Sci Transl Med (2011) 1.08
Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism. J Biol Chem (2014) 0.97
Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3β. J Clin Invest (2014) 0.97
Pathobiology of cardiac dyssynchrony and resynchronization. Heart Rhythm (2009) 0.96
Remodeling of the sarcomeric cytoskeleton in cardiac ventricular myocytes during heart failure and after cardiac resynchronization therapy. J Mol Cell Cardiol (2014) 0.89
Mitochondrial protein phosphorylation as a regulatory modality: implications for mitochondrial dysfunction in heart failure. Congest Heart Fail (2011) 0.87
Reciprocal regulation of metabolic and signaling pathways. BMC Genomics (2010) 0.87
Selection of reference genes in different myocardial regions of an in vivo ischemia/reperfusion rat model for normalization of antioxidant gene expression. BMC Res Notes (2012) 0.87
The "missing" link between acute hemodynamic effect and clinical response. J Cardiovasc Transl Res (2011) 0.84
Basic science of cardiac resynchronization therapy: molecular and electrophysiological mechanisms. Circ Arrhythm Electrophysiol (2012) 0.83
Devices in the management of advanced, chronic heart failure. Nat Rev Cardiol (2012) 0.83
Assessment of distribution and evolution of mechanical dyssynchrony in a porcine model of myocardial infarction by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 0.81
Cardiac dyssynchrony and response to cardiac resynchronisation therapy in heart failure: can genetic predisposition play a role? Neth Heart J (2016) 0.79
Glycoproteins identified from heart failure and treatment models. Proteomics (2014) 0.79
Animal models of dyssynchrony. J Cardiovasc Transl Res (2011) 0.79
Cardiac resynchronization therapy and reverse molecular remodeling: importance of mitochondrial redox signaling. Circ Res (2011) 0.79
Rethinking Resynch: Exploring Mechanisms of Cardiac Resynchroniztion Beyond Wall Motion Control. Drug Discov Today Dis Mech (2010) 0.79
Pathophysiology of dyssynchrony: of squirrels and broken bones. Neth Heart J (2016) 0.78
Usefulness of His Bundle Pacing to Achieve Electrical Resynchronization in Patients With Complete Left Bundle Branch Block and the Relation Between Native QRS Axis, Duration, and Normalization. Am J Cardiol (2016) 0.78
Pathways of the heart. Circ Cardiovasc Genet (2009) 0.77
Past, present, and future of CRT. Heart Fail Rev (2011) 0.76
The molecular fingerprint of cardiac dyssynchrony and cardiac resynchronization therapy. Heart Fail Rev (2011) 0.76
Adrenergic and cholinergic plasticity in heart failure. Circ Res (2015) 0.75
Differential Effects of Left Ventricular Pacing Sites on Regional Contraction Patterns and Global Performance. J Cardiothorac Vasc Anesth (2016) 0.75
Acute and Chronic Changes and Predictive Value of Tpeak-Tend for Ventricular Arrhythmia Risk in Cardiac Resynchronization Therapy Patients. Chin Med J (Engl) (2016) 0.75
Speckle-tracking echocardiography elucidates the effect of pacing site on left ventricular synchronization in the normal and infarcted rat myocardium. PLoS One (2014) 0.75
Local microRNA-133a downregulation is associated with hypertrophy in the dyssynchronous heart. ESC Heart Fail (2017) 0.75
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet (2001) 63.36
Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 22.81
The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J (1996) 4.11
FatiGO +: a functional profiling tool for genomic data. Integration of functional annotation, regulatory motifs and interaction data with microarray experiments. Nucleic Acids Res (2007) 3.68
Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation (1999) 3.62
Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block. Circulation (2002) 2.88
Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients. J Am Coll Cardiol (2004) 2.63
Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J (2002) 2.27
Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation (2009) 2.09
Asynchronous electrical activation induces asymmetrical hypertrophy of the left ventricular wall. Circulation (1998) 1.73
Reversal of global apoptosis and regional stress kinase activation by cardiac resynchronization. Circulation (2008) 1.67
Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation (2009) 1.63
Effects of cardiac resynchronization therapy on ventricular repolarization in patients with congestive heart failure. J Cardiovasc Electrophysiol (2005) 1.55
Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. Eur Heart J (2004) 1.36
Pathobiology of left ventricular dyssynchrony and resynchronization. Prog Cardiovasc Dis (2006) 1.35
Abnormal conduction and repolarization in late-activated myocardium of dyssynchronously contracting hearts. Cardiovasc Res (2005) 1.26
Gene expression in acute myocardial stress. Induction by hypoxia, ischemia, reperfusion, hyperthermia and oxidative stress. J Mol Cell Cardiol (1995) 1.12
Cardiac resynchronization therapy homogenizes myocardial glucose metabolism and perfusion in dilated cardiomyopathy and left bundle branch block. J Am Coll Cardiol (2003) 1.04
Altered expression of a limited number of genes contributes to cardiac decompensation during chronic ventricular tachypacing in dogs. Physiol Genomics (2006) 1.03
Key pathways associated with heart failure development revealed by gene networks correlated with cardiac remodeling. Physiol Genomics (2008) 0.89
Left ventricular geometric patterns and QT dispersion in untreated essential hypertension. Am J Hypertens (1998) 0.85
Immediate-early gene induction by repetitive mechanical but not electrical activity in adult rat cardiomyocytes. FEBS Lett (1993) 0.83
Effects of cardiac resynchronization therapy on coronary blood flow: evaluation by transthoracic Doppler echocardiography. Eur J Heart Fail (2008) 0.81
The relationship between left ventricular shape and QT interval dispersion. Echocardiography (2002) 0.80
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28
Multiple-laboratory comparison of microarray platforms. Nat Methods (2005) 11.74
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol (2005) 5.39
Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation (2007) 5.09
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation (2003) 4.51
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med (2006) 3.59
Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells (2010) 3.53
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA (2003) 3.25
Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22
End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol (2011) 3.21
DNA methylation signatures in development and aging of the human prefrontal cortex. Am J Hum Genet (2012) 3.17
Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest (2003) 3.15
The mitochondrial origin of postischemic arrhythmias. J Clin Invest (2005) 3.08
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol (2008) 2.99
Tackling heart failure in the twenty-first century. Nature (2008) 2.93
Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block. Circulation (2002) 2.88
Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation (2005) 2.80
Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy. J Am Coll Cardiol (2010) 2.66
Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging (2008) 2.64
Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging (2012) 2.62
Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol (2006) 2.61
Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension (2006) 2.59
Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation (2009) 2.55
Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol (2005) 2.53
High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation (2008) 2.47
Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol (2011) 2.38
Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation (2005) 2.38
Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood (2008) 2.36
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest (2005) 2.36
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A (2005) 2.25
L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA (2006) 2.24
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol (2002) 2.22
The future of fellowship training in clinical cardiac electrophysiology: Program directors' perspective 2008. Heart Rhythm (2009) 2.22
Two-dimensional strain--a Doppler-independent ultrasound method for quantitation of regional deformation: validation in vitro and in vivo. J Am Soc Echocardiogr (2005) 2.20
Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res (2004) 2.19
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res (2009) 2.11
Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: implications for assessing cardiac resynchronization. Circulation (2005) 2.09
Post-transcriptional gene silencing of KChIP2 and Navbeta1 in neonatal rat cardiac myocytes reveals a functional association between Na and Ito currents. J Mol Cell Cardiol (2008) 2.09
Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation (2009) 2.09
Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol (2007) 2.07
Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol (2005) 2.06
Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol (2007) 2.05
Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation (2012) 2.05
Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association. Circulation (2011) 2.05
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens (2007) 2.01
Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. J Am Coll Cardiol (2005) 1.98
Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol (2010) 1.97
Gaps in the ablation line as a potential cause of recovery from electrical isolation and their visualization using MRI. Circ Arrhythm Electrophysiol (2011) 1.95
Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy. Eur Heart J (2004) 1.95
Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res (2012) 1.95
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol (2007) 1.94
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest (2011) 1.94
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation (2011) 1.92
Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res (2005) 1.91
Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol (2005) 1.88
Na+ channel regulation by Ca2+/calmodulin and Ca2+/calmodulin-dependent protein kinase II in guinea-pig ventricular myocytes. Cardiovasc Res (2009) 1.88
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. J Am Coll Cardiol (2013) 1.86
Beat-to-beat three-dimensional ECG variability predicts ventricular arrhythmia in ICD recipients. Heart Rhythm (2010) 1.85
Pre-processing Agilent microarray data. BMC Bioinformatics (2007) 1.84
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov (2007) 1.83
Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation (2008) 1.82
Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest (2009) 1.79
A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci U S A (2003) 1.78
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol (2009) 1.77
Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A (2003) 1.76
Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol (2008) 1.75
QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2011) 1.73